CHMP recommends OTC switch for Alli
This article was originally published in Scrip
GlaxoSmithKline's application for Alli (orlistat, licensed from Roche) to be recommended for over-the-counter status in all 27 EU countries has been viewed positively by theCHMP. It is the first time the European Medicines Agency's scientific advisory committee has recommended a product for a centralised OTC switch, and the European Commission's final decision on the dossier will be watched closely.
You may also be interested in...
Local health authorities in Coventry, UK, say it is most unlikely that vaccination with GlaxoSmithKline's Cervarix (human papillomavirus vaccine) was the cause of the death of a 14-year-old schoolgirl on September 28th.
Patents on Janssen-Cilag's (Johnson & Johnson) anti-epileptic Topamax/Epitomax (topiramate) expired in many European countries on September 25th, and generics companies are launching their own versions quickly.
Lilly's Alimta (pemetrexed) has been recommended as a first-line treatment for some patients in England and Wales with non-small cell lung cancer (NSCLC) in binding guidance for the national health service.